Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.
NICE has recommended that Janssen’s Darzalex (daratumumab) should be reimbursed on an interim basis by the Cancer Drugs Fund in pre-treated multiple myeloma, after months of wrangling.
